Bolt Biotherapeutics $230 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Immunocore $297 million IPO
We advised the joint book-running managers and underwriters on the IPO and Nasdaq listing
Terns Pharmaceuticals $127.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Gracell Biotechnologies $209 million IPO and Nasdaq listing
We advised the underwriters on the IPO of ADSs
Seer $336 million IPO and concurrent private placement
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 10,592,106 shares of Class A common stock of Seer, Inc. at $19.00 per…
Maravai LifeSciences Holdings $1.863 billion IPO
Davis Polk advised the representatives of the several underwriters in connection with the initial public offering of 69,000,000 shares of Class A common stock of Maravai LifeSciences…
Olema Pharmaceuticals $240 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $240 million initial public offering of 12,650,000 shares of common stock of Olema Oncology at $19…
Signify Health acquisition of PatientBlox
Davis Polk advised Signify Health on its acquisition of PatientBlox. The acquisition accelerates Signify’s prospective provider payment capabilities for episodes of care, supporting the…
Novo Nordisk acquisition of Emisphere Technologies
Davis Polk is advising Novo Nordisk A/S on its $1.8 billion acquisition of Emisphere Technologies Inc. and related Eligen SNAC royalty stream obligations owed to MHR Fund Management LLC,…
Atea Pharmaceuticals $345 million IPO
Davis Polk advised the representatives of the underwriters in connection with the $345 million initial public offering of 14,375,000 shares of common stock of Atea Pharmaceuticals, Inc.,…